Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by 강일모, Chairman & CEO. Insider active across 2 companies, notably 케이엠제약. Aggregated, 50 filings have been published. History available since 6 March 2026. The latest transaction was filed on 13 April 2026 (Purchase). Regulator: DART (FSS). The full history is openly available.
Kang Il-mo is the Chairman & CEO of KM Pharmaceuticals, a pharmaceutical company. He leads the company's efforts to develop new medications and improve existing treatments while ensuring regulatory compliance and product quality.